Q32 Bio (NASDAQ:QTTB – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.
Insider and Institutional Ownership
31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Q32 Bio has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Q32 Bio | N/A | 50.17% | 29.49% |
| Legend Biotech | -7.21% | -8.71% | -5.40% |
Valuation and Earnings
This table compares Q32 Bio and Legend Biotech”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Q32 Bio | $53.74 million | 4.62 | $29.82 million | $3.00 | 2.78 |
| Legend Biotech | $1.03 billion | 3.51 | -$296.80 million | ($0.25) | -74.48 |
Q32 Bio has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings for Q32 Bio and Legend Biotech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Q32 Bio | 0 | 2 | 5 | 1 | 2.88 |
| Legend Biotech | 1 | 5 | 9 | 0 | 2.53 |
Q32 Bio currently has a consensus price target of $30.60, suggesting a potential upside of 266.91%. Legend Biotech has a consensus price target of $55.50, suggesting a potential upside of 198.07%. Given Q32 Bio’s stronger consensus rating and higher possible upside, research analysts plainly believe Q32 Bio is more favorable than Legend Biotech.
Summary
Q32 Bio beats Legend Biotech on 11 of the 15 factors compared between the two stocks.
About Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.
